Genomic Health Continues to Explore Using PCR-based Oncotype Dx for HER2 Testing

Genomic Health has been conducting a number of studies to examine how well its RT-PCR-based Oncotype DX test compares to IHC and FISH for assessing the HER2 status of breast cancer patients.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.